Patents Examined by Raymond Henley, III
  • Enantiomers of 2-hydroxy derivatives of fatty acids
    Patent number: 9359281
    Abstract: This invention refers to the synthesis and purification of 2 hydroxide derivatives of fatty acids, as well as to the separation method of its enantiomers (or optic isomers) [?] y [+], to the enantiomers themselves, to pharmaceutical compositions which include them, and to their use as medicines, as well as to an in vitro method of diagnosis/prognosis and evaluation of the potential use of the molecules of the invention in different pathologies, as well as their use for the regulation of certain enzymes and the study of their activity and effects.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: June 7, 2016
    Assignee: UNIVERSITAT DE LES ILLES BALEARS
    Inventors: Pablo Vicente Escribá Ruiz, María Laura Martín, María Antònia Noguera Salvà, Xavier Busquets Xaubet, David López Jiménez, Maitane Ibarguren Aizpitarte, José Javier Soto Salvador, Miguel Yus Astiz
  • Methods of nourishing animals
    Patent number: 9351998
    Abstract: The present invention relates to methods of maintaining, and methods of restoring, a desired calcium homeostasis in a non-human terrestrial animal by administering an effective amount of one or more Calcium-Sensing Receptor modulators (CaSRs) to the animal. The invention further provides methods of reducing foot lesions in chickens. The invention also relates to food compositions useful in the methods of the invention.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: May 31, 2016
    Assignee: MARICAL, INC.
    Inventors: H. William Harris, Jr., Marlies Betka, Chris Frederick Holm, Steven Harold Jury
  • Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
    Patent number: 9345692
    Abstract: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: May 24, 2016
    Assignee: OPKO Health, Inc.
    Inventors: Zhihui Qiu, Larisa Reyderman
  • Alfentanil composition for the treatment of acute pain
    Patent number: 9345698
    Abstract: There is provided pharmaceutical compositions for the treatment of pain e.g. short-term pain, which compositions comprise a mixture comprising: (a) microparticles of alfentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of alfentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: May 24, 2016
    Assignee: Orexo AB
    Inventors: Anders Pettersson, Barbro Johansson, Emil Schwan
  • Nitrile derivatives and their pharmaceutical use and compositions
    Patent number: 9340491
    Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: May 17, 2016
    Assignee: Cellceutix Corporation
    Inventor: Krishna Menon
  • HCN inhibitors affecting ganglion cell function and visual function
    Patent number: 9333208
    Abstract: The present invention is directed to a method of enhancing visual function in a subject, comprising administering to the subject in need of such enhancement, a therapeutically effective amount of an inhibitor of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the HCN channel inhibitor.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: May 10, 2016
    Inventor: Movses H. Karakossian
  • Proteasome inhibitors as ovoprotective agents to shield the ovary from chemotherapy toxicity
    Patent number: 9333212
    Abstract: A method of reducing damage to the ovary of a subject receiving chemotherapy is described. The method comprises the step of administering to the subject an amount of a proteasome inhibitor effective to reduce damage to the subject's ovary within a therapeutic time window prior to administration of a chemotherapeutic agent.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: May 10, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sana M. Salih, Elon Christiane Roti Roti
  • Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
    Patent number: 9333202
    Abstract: A method for treating a disease characterized by excessive lipofuscin accumulation in the retina in mammals afflicted therewith, comprising administering to the mammal an effective amount of a non-retinoid antagonist compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: May 10, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Janet R. Sparrow, Rando Allikmets
  • Polyurethanes for osteoimplants
    Patent number: 9327052
    Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: May 3, 2016
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David A. Knaack, John Winterbottom, David R. Kaes, Todd M. Boyce, Lawrence A. Shimp
  • Anti-inflammatory compounds
    Patent number: 9326977
    Abstract: Compositions comprising isolated ido-BR1 are described for use in therapy or prophylaxis, including the treatment of inflammatory diseases (for example as anti-inflammatory drugs) and to reduce inflammation. Also described are methods for monitoring the quality of a Cucurbitaceae extract, to processes for producing a Cucurbitaceae extract as well as to Cucurbitaceae extracts obtainable by such processes.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: May 3, 2016
    Assignee: Phytoquest Limited
    Inventor: Robert James Nash
  • Heteroaryl compounds and uses thereof
    Patent number: 9321786
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 26, 2016
    Assignees: Celgene Avilomics Research, Inc., Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Desfesoterodine salts
    Patent number: 9315450
    Abstract: The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: April 19, 2016
    Assignee: ratiopharm GmbH
    Inventors: Simone Eichner, Wolfgang Albrecht
  • Topical formulations, systems and methods
    Patent number: 9308181
    Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 12, 2016
    Assignee: Nuvo Research Inc.
    Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Tejas Desai, Wade A. Hull
  • High-affinity small molecule formylpeptide receptor ligands from screening of combinatorial mixture-based libraries
    Patent number: 9310364
    Abstract: The present invention provides novel methods and assays for high-throughput screening of combinatorial libraries to identify FPR1 and/or FPR2 ligands (e.g., agonists and/or antagonists), preferably FPR1 agonists and/or FPR2 antagonists, by positional scanning deconvolution. The invention also provides novel FPR1 and FPR2 ligands (e.g, agonists and antagonists), related pharmaceutical compositions and methods of treating FPR1 and FPR2-related disorders.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: April 12, 2016
    Assignees: STC.UNM, TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
    Inventors: Bruce S. Edwards, Larry A. Sklar, Clemencia Pinilla, Richard A. Houghten, Jon R. Appel, Marc A. Giulianotti, Jose Medina-Franco
  • Non-aqueous taxane formulations and methods of using the same
    Patent number: 9308195
    Abstract: Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: April 12, 2016
    Assignee: Teikoku Pharma USA, Inc.
    Inventor: Kiichiro Nabeta
  • Autoimmune and inflammatory disorder therapy
    Patent number: 9301961
    Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 5, 2016
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Jean Herman, Thierry Louat, Qiuya Huang, Bart Vanderhoydonck, Mark Waer, Piet Herdewijn
  • Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-?B activation
    Patent number: 9301945
    Abstract: The disclosure is directed to methods for treating inflammatory conditions and cancers that have misregulated NF-?B. In some embodiments, the disclosure is directed to methods for treating inflammatory conditions, inflammatory states associated with treating HIV and AIDS infections, and cancers that include administering strontium ranelate to a subject diagnosed with or at risk of inflammatory conditions, inflammatory states, and cancers, respectively.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: April 5, 2016
    Assignee: Emory University
    Inventors: M. Neale Weitzmann, Masayoshi Yamaguchi
  • Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
    Patent number: 9295687
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 29, 2016
    Assignee: THE MEDICINES COMPANY
    Inventors: Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
  • Synergistic pesticidal compositions and related methods
    Patent number: 9295258
    Abstract: A pesticidal composition comprises a synergistically effective amount of an ecdysone receptor agonist compound and a pesticide selected from N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (I), N-(3-chloro-1-(pyridine-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl)propanamide (II), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests. A method of protecting a plant from infestation and attack by insects comprises contacting the plant with the synergistic pesticidal composition.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 29, 2016
    Assignee: Dow AgroSciences LLC
    Inventors: Luis E. Gomez, Ricky Hunter, Mike Shaw, Tony K. Trullinger, Mary E. Kubiszak
  • Metalloporphyrin neurological treatments
    Patent number: 9295674
    Abstract: Methods and compositions for treating a subject suffering from exposure to a chemical threat agent are disclosed.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: March 29, 2016
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventor: Manisha Patel